Wave Life Scienc Stock Price, News & Analysis

Wave Life Sciences announced key developments in its third quarter 2022 report, highlighting progress in clinical trials for Huntington’s disease (WVE-003) and Duchenne muscular dystrophy (WVE-N531). The SELECT-HD trial showed safe, well-tolerated doses and a reduction in mutant huntingtin protein. WVE-006 was selected for alpha-1 antitrypsin deficiency, with CTA submissions expected in 2023. Financially, the company reported a net loss of $39 million and a significant revenue drop to $0.3 million, mainly due to prior collaboration amendments. Cash on hand is $122 million, expected to last through 2023.

Wave Life Sciences Ltd. (Nasdaq: WVE) announced that CEO Paul Bolno will participate in an analyst-led fireside chat at the Stifel 2022 Healthcare Conference in New York City on November 16, 2022, at 3:35 p.m. ET. This event focuses on the company's commitment to developing genetic medicines for devastating diseases. A live webcast of the discussion will be available on the company’s Investor Relations page, with replays accessible for a limited time post-event.

Wave Life Sciences (Nasdaq: WVE) announced a conference call scheduled for 8:30 a.m. ET on November 10, 2022, to discuss its Q3 2022 financial results and provide a business update. The call will be accessible via the company’s investor relations webpage. Wave Life Sciences is a clinical-stage genetic medicines company focused on developing treatments for severe diseases using its proprietary PRISM platform for drug development. The archived call will also be available post-event.

Wave Life Sciences Ltd. (Nasdaq: WVE) announced its participation in upcoming scientific conferences to showcase advancements in oligonucleotide chemistry and RNA editing. This includes preclinical data for WVE-006, targeting alpha-1 antitrypsin deficiency, which is presented for the first time. The presentations at the Oligonucleotide Therapeutics Society and European Society of Gene & Cell Therapy meetings will emphasize the company's proprietary discoveries and drug development capabilities.

Wave Life Sciences highlighted its advanced candidate, WVE-006, for treating alpha-1 antitrypsin deficiency (AATD) during a recent virtual event. The RNA editing program aims to correct genetic mutations and restore functional protein levels. Preclinical data show a significant increase in AAT protein production and functional activity. Clinical trial applications for WVE-006 are expected to be submitted in 2023. Wave is also exploring broader applications for its AIMers technology beyond AATD, potentially impacting multiple diseases.

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company, announced that CEO Paul Bolno will participate in an analyst-led fireside chat at Chardan’s 6th Annual Genetic Medicines Conference on October 4, 2022, at 3:15 p.m. ET in New York City. A live webcast of the event will be accessible on the company's Investor Relations page, with a replay available for a limited time afterward. Wave Life Sciences focuses on developing innovative treatments for genetically defined diseases through its proprietary PRISM platform.

Wave Life Sciences Ltd. announces positive results from the SELECT-HD Phase 1b/2a clinical trial of WVE-003, a candidate for treating Huntington’s disease. Single doses of 30 or 60 mg led to a mean reduction of 22% in mutant huntingtin protein levels in cerebrospinal fluid, with a median reduction of 30%. The treatment was reportedly well-tolerated, with no serious adverse events. Wave plans to expand the dosing cohorts and has early data supporting allele-selective knockdown of the harmful protein. Further updates are expected in 1H 2023.

Wave Life Sciences (Nasdaq: WVE) announced an analyst and investor webcast on September 28, 2022, focusing on WVE-006, its first-in-class RNA editing candidate targeting alpha-1 antitrypsin deficiency (AATD). The event, titled 'Towards the Clinic: Spotlight on RNA Editing for AATD', will provide insights from AATD expert Dr. D. Kyle Hogarth and the Wave management team. WVE-006 aims to correct mutations in the SERPINA1 gene, addressing both lung and liver disease. Registration is available on Wave's website.

Wave Life Sciences (WVE) announced the selection of WVE-006 as its first RNA editing candidate for treating alpha-1 antitrypsin deficiency (AATD), with clinical trial applications expected in 2023. The company reported a net loss of $41.3 million for Q2 2022, down from $38.8 million a year earlier, with revenue declining to $0.4 million. Research and development expenses were $29.7 million, while general and administrative expenses increased to $12.8 million. A successful financing round in June 2022 raised $70 million, strengthening the balance sheet and providing cash runway until the end of 2023.